ADMA Biologics Inc (ADMA): Price and Financial Metrics


ADMA Biologics Inc (ADMA): $1.26

0.15 (+13.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

ADMA POWR Grades


  • ADMA scores best on the Growth dimension, with a Growth rank ahead of 79.22% of US stocks.
  • ADMA's strongest trending metric is Growth; it's been moving up over the last 52 weeks.
  • ADMA ranks lowest in Quality; there it ranks in the 0th percentile.

ADMA Stock Summary

  • As for revenue growth, note that ADMA's revenue has grown 56.02% over the past 12 months; that beats the revenue growth of 87.99% of US companies in our set.
  • In terms of volatility of its share price, ADMA is more volatile than 86.11% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMA comes in at -69.63% -- higher than that of only 3.89% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Adma Biologics Inc are NGVT, LNDC, LXFR, ASUR, and CLS.
  • ADMA's SEC filings can be seen here. And to visit Adma Biologics Inc's official web site, go to www.admabiologics.com.

ADMA Valuation Summary

  • ADMA's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
  • ADMA's EV/EBIT ratio has moved up 2.2 over the prior 96 months.
  • Over the past 96 months, ADMA's price/sales ratio has gone down 41.8.

Below are key valuation metrics over time for ADMA.

Stock Date P/S P/B P/E EV/EBIT
ADMA 2021-08-31 3.1 1.6 -2.4 -3.8
ADMA 2021-08-30 3.0 1.6 -2.4 -3.7
ADMA 2021-08-27 3.2 1.6 -2.5 -3.9
ADMA 2021-08-26 3.2 1.6 -2.5 -3.9
ADMA 2021-08-25 3.2 1.7 -2.5 -3.9
ADMA 2021-08-24 3.1 1.6 -2.5 -3.8

ADMA Growth Metrics

  • Its year over year price growth rate is now at -47.81%.
  • The 4 year price growth rate now stands at -46.04%.
  • The 4 year net income to common stockholders growth rate now stands at -186.96%.
Over the past 67 months, ADMA's revenue has gone up $50,934,020.

The table below shows ADMA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 58.11165 -121.5629 -73.61047
2021-03-31 48.06866 -110.5851 -74.88326
2020-12-31 42.21978 -102.003 -75.74855
2020-09-30 40.30074 -89.43556 -66.9018
2020-06-30 37.24689 -89.2138 -61.42281
2020-03-31 36.02024 -86.55328 -54.45659

ADMA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMA has a Quality Grade of F, ranking ahead of 0.13% of graded US stocks.
  • ADMA's asset turnover comes in at 0.268 -- ranking 168th of 680 Pharmaceutical Products stocks.
  • NOVN, ZYNE, and VBIV are the stocks whose asset turnover ratios are most correlated with ADMA.

The table below shows ADMA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.268 -0.163 -0.264
2021-03-31 0.233 -0.295 -0.291
2020-12-31 0.211 -0.452 -0.318
2020-09-30 0.224 -0.337 -0.296
2020-06-30 0.223 -0.341 -0.290
2020-03-31 0.233 -0.303 -0.279

ADMA Price Target

For more insight on analysts targets of ADMA, see our ADMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.67 Average Broker Recommendation 1.4 (Strong Buy)

ADMA Stock Price Chart Interactive Chart >

Price chart for ADMA

ADMA Price/Volume Stats

Current price $1.26 52-week high $3.11
Prev. close $1.11 52-week low $1.01
Day low $1.01 Volume 14,319,977
Day high $1.27 Avg. volume 4,396,782
50-day MA $1.24 Dividend yield N/A
200-day MA $1.75 Market Cap 166.63M

ADMA Biologics Inc (ADMA) Company Bio


ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.


ADMA Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMA Latest Social Stream


Loading social stream, please wait...

View Full ADMA Social Stream

Latest ADMA News From Around the Web

Below are the latest news stories about Adma Biologics Inc that investors may wish to consider to help them evaluate ADMA as an investment opportunity.

ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in stra

Yahoo | October 18, 2021

ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced on-demand access to an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Childrens Hospital. During the live presentation and question and answer session, Dr. Walter discussed real-world experiences in patients that were successfully treated with ADMAs ASCENIV, a novel intravenous immunoglobulin (IVIG) produ...

Intrado Digital Media | October 4, 2021

ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Childrens Hospital. Two leading experts in the management of respiratory syncytial virus (RSV) and other respiratory viruses in immunocompromised patients will discuss todays key clinical challenges and emerging treatment strategies. A novel intravenous im...

Intrado Digital Media | October 1, 2021

Adma Biologics Insider Trades $300K In Company Stock

Joseph Edelman, 10% Owner at Adma Biologics (NASDAQ:ADMA), made a large insider sell on September 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Edelman sold 260,603 shares of Adma Biologics at prices ranging from $1.12 to $1.22. The total transaction amounted to $299,236. Edelman still owns a total of 13,262,375 shares of Adma Biologics worth, $14,978,526. Adma Biologics shares are trading down 0.05% at

Yahoo | October 1, 2021

10% Owner Of Adma Biologics Sold $620K In Stock

Joseph Edelman, 10% Owner at Adma Biologics (NASDAQ:ADMA), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Edelman sold 500,000 shares of Adma Biologics at prices ranging from $1.23 to $1.26. The total transaction amounted to $622,500. Following the transaction, Edelman still owns 13,522,978 shares of Adma Biologics worth $15,381,035. Adma Biologics shares are trading u

Yahoo | September 30, 2021

Read More 'ADMA' Stories Here

ADMA Price Returns

1-mo 0.80%
3-mo -21.74%
6-mo -33.68%
1-year -41.80%
3-year -77.09%
5-year -79.84%
YTD -35.38%
2020 -51.25%
2019 67.36%
2018 -25.55%
2017 -37.30%
2016 -36.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7785 seconds.